SLC2A1 and ovarian carcinoma: SLC2A1 is the most extensively studied in a wide range of malignancies, like such as prostate, ovarian cancer, and breast as well as bladder cancers, while abnormally high GLUT1 expression correspondence with the malignant phenotype of tumors [47–50].